Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Somatostatinoma × Sunitinib × Clear all

Phase

Phase NA 1 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Renal Cell 52 Neoplasm Metastasis 19 Kidney Neoplasms 18 Breast Neoplasms 14 Carcinoma, Non-Small-Cell Lung 13 Neoplasms 11 Urinary Bladder Neoplasms 10 Prostatic Neoplasms 9 Lung Neoplasms 7 Glioblastoma 6 Gastrointestinal Stromal Tumors 6 Colorectal Neoplasms 6 Brain Neoplasms 6 Thymoma 5 Small Cell Lung Carcinoma 5 Ovarian Neoplasms 5 Neuroendocrine Tumors 5 Melanoma 5 Liver Neoplasms 5 Carcinoma 5 Uveal Melanoma 4 Thyroid Neoplasms 4 Sarcoma 4 Recurrence 4 Pancreatic Neoplasms 4 Multiple Myeloma 4 Esophageal Neoplasms 4 Adenocarcinoma 4 Urethral Neoplasms 3 Thyroid Cancer, Papillary 3

Interventions

Capecitabine 5 Temozolomide 4 Octreotide 3 Magnetic Resonance Spectroscopy 2 Leucovorin 2 Fluorouracil 2 Cisplatin 2 Bortezomib 2 Bevacizumab 2 vatalanib 1 temsirolimus 1 sapanisertib 1 romidepsin 1 regorafenib 1 pentetreotide 1 pazopanib 1 palbociclib 1 motesanib diphosphate 1 lutetium Lu 177 dotatate 1 irinotecan sucrosofate 1 gallium Ga 68 dotatate 1 dehydroftorafur 1 batifiban 1 aflibercept 1 Thalidomide 1 Sunitinib 1 Streptozocin 1 Specimen Handling 1 Sirolimus 1 Panobinostat 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02230176 2025-04-20

OCCLURANDOM

Gustave Roussy, Cancer Campus, Grand Paris

Phase 2 Completed

Somatostatinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡